Melanoma gene and epigenetic switches that reshape the tumor environment
Targetable epigenetic and transcriptional mechanisms in melanoma thatshape the microenvironment
The team aims to reverse melanoma's hidden gene and epigenetic switches so patients' immune systems can better recognize and destroy tumor cells.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11184315 on NIH RePORTER |
What this research studies
This program examines how changes in melanoma cells' genes and epigenetic marks help tumors hide from the immune system. Researchers use molecular experiments, animal models, and advanced live-imaging tools to watch how tumors interact with immune cells. They are testing ways to block a protease called DDI2 and repurpose an FDA-approved inhibitor to boost antigen presentation and T cell–mediated killing. The work is collaborative across multiple labs and is designed to move promising findings toward treatments that could be offered to patients.
Who could benefit from this research
Good fit: Patients with cutaneous melanoma, especially those with advanced or treatment-resistant disease, would be most likely candidates for future related trials or sample-donation opportunities.
Not a fit: People with cancers other than melanoma or those with very early-stage melanoma unlikely to need immune-based therapy may not directly benefit from these findings.
Why it matters
Potential benefit: If successful, this work could make melanoma tumors more visible to the immune system and improve responses to immunotherapy.
How similar studies have performed: Previous research has shown that improving antigen presentation can enhance immune responses and clinical benefit for some patients, while targeting DDI2 as described here is a newer, less-tested approach.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Fisher, David E — Massachusetts General Hospital
- Study coordinator: Fisher, David E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.